Scientist at UK’s first convergent science centre looking to use microbubbles to destroy cancer

As part of the new £13 million Cancer Research UK Convergence Science Centre at The Institute of Cancer Research, scientists are “re-imagining ultrasound technology to develop a treatment that can liquefy cancer cells in the body using microscopic bubbles” Cancer Research UK has announced the development of the new treatment that doesn’t require invasive surgery, in

Continue Reading

Gilead and Lyndra to collab on long acting oral HIV drugs

US-based Lyndra Therapeutics has signed an agreement with Gilead Sciences to develop and commercialise ultra-long acting oral therapies to treat HIV. Gilead will have exclusive rights to leverage Lyndra’s proprietary long-acting drug development platform for HIV therapies. Lyndra was founded in 2015 with the aim of improving medication adherence by focusing on developing longer acting

Continue Reading

Oxford Biomedica and Santen sign ophthalmology R&D deal

UK biotech Oxford Biomedica and Japanese Santen have begun an option and licence agreement to research and develop gene therapy products for an inherited retinal disease. Inherited retinal diseases are a group of rare disorders caused by one of more than 260 different genes where mutation results in vision loss or blindness, often disproportionally affecting

Continue Reading

UK scientists find new compound that kills antibiotic-resistant superbugs

A new compound which visualises and kills antibiotic resistant superbugs has been discovered by scientists at the University of Sheffield and Rutherford Appleton Laboratory (RAL). A team led by Professor Jim Thomas, from the University of Sheffield’s Department of Chemistry, is testing new compounds developed by his PhD student Kirsty Smitten, on antibiotic resistant gram-negative

Continue Reading